Gunjan Thakur’s Post

The Global HbA1c Testing Market is projected to soar with a remarkable growth rate of 9-12% by 2028! 📈 As diabetes prevalence continues to rise worldwide, routine HbA1c testing plays a crucial role in effective diabetes management. Patients are increasingly recognizing the significance of regular testing, leading to a surge in demand for less-invasive and accurate testing methods. Some of the key players operating in the market are Abbott, Bio-Rad Laboratories, ARKRAY,Inc., Danaher Corporation, Roche, Siemens Healthineers, Transasia Bio-Medicals Ltd., Trinity Biotech, EKF Diagnostics, Beckman Coulter Diagnostics, and Randox among others. Unlock valuable market insights, request your sample report now https://lnkd.in/dBR-hGP8 Join us in the journey towards better diabetes management and improved healthcare outcomes! 💪 #HealthcareInnovation #DiabetesManagement #HbA1cTesting #GlobalHealthcare #HealthTech #MedicalInnovation #HealthcareIndustry #HealthcareTechnology #MedicalDevices #HealthAwareness #PatientCare #HealthEquity #HealthForAll #DigitalHealth #InnovationInHealthcare #HealthcareTrends #MedicalResearch #GlobalHealth #HealthcareProviders #PublicHealth #HealthyLiving #DiabetesAwareness #HealthAndWellness #HealthcareSolutions #HbA1c #GlycatedHemoglobin #DiabetesTesting #BloodSugarControl #A1cTest #DiabetesCare #GlucoseMonitoring #Endocrinology #DiabetesPrevention #BloodSugarLevels #Type1Diabetes #Type2Diabetes #InsulinResistance #MetabolicHealth #HealthyBloodSugar #ContinuousGlucoseMonitoring #HealthCheck #PreventiveCare

The landscape of #DigitalHealth solutions for #DiabetesManagement is rapidly evolving, and I was excited to read the latest report comparing different digital solutions. With almost one in ten people globally affected by type 2 diabetes, finding effective ways to manage this condition is more crucial than ever. The report reviews the efficacy of eight digital diabetes management tools aimed at improving glycemic control in patients. Key Takeaways: 1️⃣ Remote Patient Monitoring: While aiming to enhance glycemic control, these solutions didn't demonstrate significant clinical benefits over usual care. 2️⃣ Behavior and Lifestyle Modification: Despite incorporating diverse programs, the evidence suggests minimal and short-term improvements in glycemic control. 3️⃣ Nutritional Ketosis: Exceptions were observed, particularly for individuals with higher HbA1c levels and those pursuing diabetes remission through nutritional ketosis, however, the quality of evidence for this was low. You can read the report here: https://lnkd.in/d8pxKpTr Let's continue the conversation towards better healthcare outcomes! #HealthcareInnovation

Could glucose-responsive insulin (GRI) be the answer to transforming diabetes care for hundreds of millions of people worldwide? Carbometrics has collaborated with leading global healthcare company Novo Nordisk to conduct cutting-edge research into GRIs—a type of smart insulin that responds dynamically to varying glucose levels in blood—and their potential for revolutionising diabetes treatment, and the findings were published in today's Nature paper (Nature Magazine): https://lnkd.in/eF5vbKkX Carbometrics is a biotech startup developing the world’s most selective synthetic Glucose Binding Molecule (GBM) to support reliable and accurate diabetes management. It was spun-out from Ziylo following Ziylo's acquisition by Novo Nordisk in 2018 to accelerate the healthcare leader's development of GRIs - Ziylo was founded by Harry Destecroix, who went on to found Science Creates. As a Science Creates member company and SCVC portfolio company, Carbometrics specialises in the design, synthesis, and derivatisation of highly selective and robust synthetic Glucose Binding Molecules. Find out more about their novel tech here: https://lnkd.in/exnvPA8m It's great to see the work this team is doing to empower millions to improve their lifestyles. #deeptech #biotech #diabetescare #innovation

We are delighted to unveil our latest groundbreaking research on glucose-responsive insulins (GRIs), in collaboration with Novo Nordisk and University of Bristol, as featured in Nature. This study marks a major advancement in Carbometrics’ mission to transform diabetes care. 📑💡 Our team's efforts have led to the development of 'smart' insulins capable of dynamically responding to changes in blood glucose levels. This innovation could ultimately lead to a safer and more effective approach to insulin therapy, potentially revolutionising how diabetes is managed worldwide. 🌍🩺 Thank you to Novo Nordisk and our dedicated team for their commitment to advancing healthcare solutions. We look forward to further reducing the burden on people living with diabetes and shaping the future of diabetes treatment. 🚀💙 Join us in celebrating this milestone achievement! Follow the links below to learn more about our research and its impact on diabetes care: Glucose-Sensitive Insulin — Carbometrics: https://lnkd.in/exnvPA8m Smart insulin switches itself off in response to low blood sugar — Nature News & Views: https://lnkd.in/eupNzW7P Glucose-sensitive insulin with attenuation of hypoglycaemia — Nature article: https://lnkd.in/eF5vbKkX #Healthcare #Diabetes #Insulin #GRI #Type1Diabetes #T1D #NovoNordisk #Carbometrics #Bristol #Research

🎉 𝗔𝗻𝗼𝘁𝗵𝗲𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗔𝗽𝗽 𝗝𝗼𝗶𝗻𝘀 𝗢𝘂𝗿 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: 𝗗𝗶𝗯𝗶, 𝗦𝗽𝗼𝗻𝘀𝗼𝗿𝗲𝗱 𝗯𝘆 Novo Nordisk 🎉 We’re beyond excited to officially announce the launch of Dibi, our newest digital companion app for managing Type 2 diabetes, sponsored by Novo Nordisk. Dibi is designed to support patients at every stage of their diabetes journey, with a special focus on those beginning insulin therapy. Created with insights from both patients and healthcare professionals, the app offers tailored features to simplify disease management and empower users to take charge of their health. With Dibi, we are proud to take another significant step toward personalized and patient-centered healthcare! For more details about this exciting development, check our latest announcement 👉 https://lnkd.in/dmnmCGWb #DigitalHealth #DiabetesCare #PatientEmpowerment #RealWorldEvidence #Dibi 

#Automatic_Pill_Dispenser Market size of nearly USD 7.44 Billion by 2032 from USD 3.44 Billion in 2023 with a CAGR of 8.93% under the study period 2024-2032. https://lnkd.in/dvaWn3Sy The growth of the automatic pill #dispenser market is propelled by the increasing prevalence of chronic #diseases and conditions that require long-term medication management, such as #diabetes, hypertension, and cardiovascular diseases. Automatic pill #dispensers provide a reliable solution for patients to manage their #medication schedules accurately, reducing the risk of missed or incorrect doses. BD Dickinson Williams & Company Capsa Healthcare ARxIUM Accu-Chart Plus Healthcare Systems, Inc. Accu-Chart Plus Healthcare Systems, Inc. Tenet Healthcare Cerner Corporation Hero Health ScriptPro Medipense Inc. InstyMeds MedMinder Omnicell Pharmacell Medication Systems Ltd. Swisslog Healthcare McKesson Corporation

Diabetes is a growing concern in Singapore, with numbers projected to rise significantly.😱 Thankfully, advancements in technology—like continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems—are revolutionizing diabetes care. These innovations, supported by research, help individuals manage their condition more effectively, improving quality of life. 🌟💡 As we move forward, how can technology and research continue to shape the future of healthcare for chronic conditions?🤖 #HealthInnovation #HealthTech #DiabetesCare #HealthcareRevolution

Check out these upcoming webinars …valuable information that women managing diabetes need!

🚨 Exciting Development in Diabetes Care! 🚨 Zydus Group has partnered with CVS Caremark to include Zituvio™, Zituvimet™, and Zituvimet™ XR in its formulary. These innovative therapies aim to provide better glycemic control for adults with type 2 diabetes, making quality healthcare more accessible. This collaboration highlights Zydus Group commitment to addressing lifestyle diseases while reinforcing its footprint in the $10B U.S. diabetes market. 💡 Insight: Strategic partnerships are shaping the future of affordable healthcare globally. Follow Harshal Jain for the latest insights into the healthcare world! #Healthcare #PharmaUpdates #IndiaPharma #PharmaceuticalIndustry #Harshal #HJ

📜Research Article : ✍🏻Sona Warrier, #Patient #Profiling and #Outcome #Assessment of #Vildagliptin and #Dapagliflozin #FDC in #Persons with #Type 2 #Diabetes #Mellitus #ABSTRACT #Introduction: Type 2 Diabetes Mellitus (T2D) is a condition characterized by rapid progression, and in certain instances, managing glucose levels may not be adequately achieved with a single pill. Vildagliptin and dapagliflozin in a Fixed-Dose Combination (FDC) complement each other’s actions, aiding in the control of glycemia.... #Methods: Retrospective data from T2D patients who were prescribed the FDC and had two follow-up visits between May 1, 2022, and January 31, 2023, were enrolled in the study.... #Results: The average age of the study sample was 55.8 years, with nearly two-thirds being male (65.5%). At 6 months after FDC medication, glycated hemoglobin (HbA1c) significantly decreased by 1.2% (Baseline: 8.4%, Follow-up: 7.2%, p-value <0.001), indicating improved glycemic control.... #Conclusion: The Fixed Dose Combination of Vildagliptin and Dapagliflozin effectively enhances glycemic control by demonstrating a significant reduction in mean HbA1c levels after six months compared to baseline.... 📰 Get full-length article here: https://lnkd.in/gfuCMBkp We do accept #PPTs and #Video Articles to be publish within our Journal. You can send us your article to given email #Email: onlinescientificresearch@gmail.com